Welcome!

News Feed Item

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of collaborative R&D financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of collaborative R&D deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Report scope

Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in collaborative R&D dealmaking in the biopharma industry since 2009
Analysis of collaborative R&D deal structure
Case studies of real-life collaborative R&D deals
Comprehensive listing of collaborative R&D deals since 2009
Access to collaborative R&D contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading collaborative R&D deals by value since 2009
Most active collaborative R&D dealmakers since 2009
The leading collaborative R&D partnering resources

In Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in collaborative R&D dealmaking

2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2009
2.7. The future of collaborative R&D deals

Chapter 3 – Overview of collaborative R&D deal structure

3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica – June 2013
3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals – January 2013
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013

Chapter 4 – Leading collaborative R&D deals

4.1. Introduction
4.2. Top collaborative R&D deals by value
4.3. Most active collaborative R&D dealmakers
4.3.1 Most active collaborative R&D dealmakers by therapy
4.3.2. Most active collaborative R&D dealmakers by stage of development
4.4. Bigpharma collaborative R&D deal activity
4.4. Bigbiotech collaborative R&D deal activity

Chapter 5 – Collaborative R&D deal term benchmarks

5.1. Introduction
5.2. Collaborative R&D headline values
5.5.2. Collaborative R&D upfront payments
5.2.3. Collaborative R&D milestone payments
5.2.4. Collaborative R&D royalty rates

Chapter 6 – Bigpharma collaborative R&D deals

6.1. Introduction
6.2. How to use collaborative R&D deals
6.3. Big pharma collaborative R&D agreement listings

Chapter 7 – Bigbiotech collaborative R&D deals

7.1. Introduction
7.2. How to use collaborative R&D deals
7.3. Big biotech collaborative R&D agreement listings

Chapter 8 – Collaborative R&D contract directory 2009-2014

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendices

Appendix – Resources
Appendix – Deal type definitions
Appendix 1 – Collaborative R&D dealmaking - by financial disclosure
Appendix 2 – Collaborative R&D - by companies A-Z
Appendix 3 – Collaborative R&D - by stage of development
Appendix 4 – Collaborative R&D - by therapeutic target
Appendix 5 – Collaborative R&D - by technology type

About Wildwood Ventures

Current Partnering
Current Agreements

TABLE OF FIGURES

Figure 1: Definition of collaborative R&D
Figure 2: Situations where collaborative R&D can prove useful
Figure 3: Key attributes of a collaborative R&D deal
Figure 4: Trends in collaborative R&D deal announcements, 2009-2014
Figure 5: Collaborative R&D deals signed at each phase of development, 2009-2014
Figure 6: Collaborative R&D deals by therapy area, 2009-2014
Figure 7: Collaborative R&D agreements – what should a contract include?
Figure 8: Components of the collaborative R&D deal structure
Figure 9: Top collaborative R&D deals by value since 2009
Figure 10: Most active collaborative R&D dealmakers 2009-2014
Figure 11: Most active collaborative R&D dealmakers 2009-2014 by therapy
Figure 12: Most active collaborative R&D dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – collaborative R&D deals 2009 to 2014
Figure 14: Bigpharma collaborative R&D deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – collaborative R&D deals 2009 to 2014
Figure 16: Bigbiotech collaborative R&D deal frequency - 2009 to 2014
Figure 17: Collaborative R&D deal headline value distribution, US$million – discovery stage
Figure 18: Collaborative R&D deal headline value distribution, US$million – preclinical stage
Figure 19: Collaborative R&D deal headline value distribution, US$million – phase I stage
Figure 20: Collaborative R&D deal headline value distribution, US$million – phase II stage
Figure 21: Collaborative R&D deal headline value distribution, US$million – phase III stage
Figure 22: Collaborative R&D deal headline value distribution, US$million – regulatory stage
Figure 23: Collaborative R&D deal headline value distribution, US$million – marketed stage
Figure 24: Summary median Collaborative R&D headline value by stage of development, 2009-2014
Figure 25: Collaborative R&D deal upfront payment distribution, US$million – discovery stage
Figure 26: Collaborative R&D deal upfront payment distribution, US$million – preclinical stage
Figure 27: Collaborative R&D deal upfront payment distribution, US$million – phase I stage
Figure 28: Collaborative R&D deal upfront payment distribution, US$million – phase II stage
Figure 29: Collaborative R&D deal upfront payment distribution, US$million – phase III stage
Figure 30: Collaborative R&D deal upfront payment distribution, US$million – regulatory stage
Figure 31: Collaborative R&D deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median collaborative R&D upfront payments by stage of development, 2009-2014
Figure 33: Collaborative R&D deal milestone distribution, US$million – discovery stage
Figure 34: Collaborative R&D deal milestone distribution, US$million – preclinical stage
Figure 35: Collaborative R&D deal milestone distribution, US$million – phase I stage
Figure 36: Collaborative R&D deal milestone distribution, US$million – phase II stage
Figure 37: Collaborative R&D deal milestone distribution, US$million – phase III stage
Figure 38: Collaborative R&D deal milestone distribution, US$million – regulatory stage
Figure 39: Collaborative R&D deal milestone distribution, US$million – marketed stage
Figure 40: Collaborative R&D deals with royalty rates, %
Figure 41: Collaborative R&D deal royalty rate distribution, US$million – discovery stage
Figure 42: Collaborative R&D deal royalty rate distribution, US$million – preclinical stage
Figure 43: Collaborative R&D deal royalty rate distribution, US$million – phase I stage
Figure 44: Collaborative R&D deal royalty rate distribution, US$million – phase II stage
Figure 45: Collaborative R&D deal royalty rate distribution, US$million – phase III stage
Figure 46: Collaborative R&D deal royalty rate distribution, US$million – regulatory stage
Figure 47: Collaborative R&D deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median collaborative R&D royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

Read the full report:
Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
As more and more companies are making the shift from on-premises to public cloud, the standard approach to DevOps is evolving. From encryption, compliance and regulations like GDPR, security in the cloud has become a hot topic. Many DevOps-focused companies have hired dedicated staff to fulfill these requirements, often creating further siloes, complexity and cost. This session aims to highlight existing DevOps cultural approaches, tooling and how security can be wrapped in every facet of the bu...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
In his session at @ThingsExpo, Dr. Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, presented the findings of a series of six detailed case studies of how large corporations are implementing IoT. The session explored how IoT has improved their economic performance, had major impacts on business models and resulted in impressive ROIs. The companies covered span manufacturing and services firms. He also explored servicification, how manufacturing firms shift from se...
Connecting to major cloud service providers is becoming central to doing business. But your cloud provider’s performance is only as good as your connectivity solution. Massive Networks will place you in the driver's seat by exposing how you can extend your LAN from any location to include any cloud platform through an advanced high-performance connection that is secure and dedicated to your business-critical data. In his session at 21st Cloud Expo, Paul Mako, CEO & CIO of Massive Networks, wil...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...